PCRX — Pacira BioSciences, Inc.
Is PCRX overbought or oversold? Here is the current MarketMoodz read.
Pacira BioSciences, Inc. (PCRX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $36.48. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$36.48
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all oversold Healthcare stocks →
AI analysis
Pacira BioSciences, Inc. exhibits a mixed profile: established positioning in non-opioid perioperative analgesia and potential upside from specialty distribution trends and possible strategic interest from larger pharma, balanced by exposure to hospital procedure volumes, reimbursement uncertainty, and a recent negative 8-K that raises short-term execution risk. Financial health is tied to sustained adoption of core products and margin recovery; catalysts include improved OR volumes, clearer guidance from management, or an inorganic strategic move. Near-term sentiment is cautious, so outcomes will hinge on upcoming quarterly updates and any clarification around the 8-K.
Key factors
- Leading specialist in non-opioid, perioperative analgesia with established branded product franchise and hospital relationships
- Revenue and margin sensitivity to hospital procedure volumes and OR utilization trends
- Distributor and specialty-channel tailwinds as chronic injectable and specialty therapy flows increase
- Potential M&A interest from larger pharma given sector consolidation trends, which could support upside
- Recent 8-K filing and ambiguous market tone create near-term uncertainty in investor sentiment
Risks
- Reimbursement pressure and program integrity changes in Medicare Advantage that could squeeze hospital/insurer economics
- Competitive pressure from generics, alternative analgesic technologies or new entrants (including device-assisted approaches)
- Operational or manufacturing issues reflected in recent 8-K could weigh near-term results and guidance
- Concentration risk on a limited number of core products; slower adoption of newer assets would hamper growth
- Macro/market risk from rate-path uncertainty reducing appetite for cyclical or mid-cap healthcare stocks
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for PCRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.